澳大利亚和新西兰特发性肺纤维化治疗立场声明
该立场声明由澳大利亚和新西兰胸科学会及澳大利亚肺基金会制定,旨在总结特发性肺纤维化(IPF)治疗的当前证据,尤其针对澳新人群。文中讨论了抗纤维化药物尼达尼布和吡非尼酮的广泛应用,并涉及非药物治疗及证据缺乏领域。
要点
- IPF中位生存期仅2-5年,特征为进行性呼吸困难和肺功能恶化。
- 2014年两项里程碑试验后,尼达尼布和吡非尼酮获广泛批准用于IPF治疗。
- 声明还讨论肺康复、氧疗等症状管理及证据缺乏领域。
核心结论
- 抗纤维化药物尼达尼布和吡非尼酮已获广泛批准,基于2014年两项里程碑临床试验。
- 需关注证据缺乏领域,尤其是更广泛的IPF严重程度谱和合并症治疗。
研究设计与样本
- 制定机构:澳大利亚和新西兰胸科学会与澳大利亚肺基金会。
- 方法:立场声明,基于当前证据综述。
主要发现
- IPF为不明病因的纤维化间质性肺疾病,中位生存期仅2-5年。
- 特征为进行性呼吸困难和肺功能恶化,最终导致死亡。
- 2014年两项里程碑临床试验发表后,尼达尼布和吡非尼酮获广泛批准。
临床怎么用
- 考虑使用抗纤维化药物尼达尼布和吡非尼酮治疗IPF。
- 非药物治疗如肺康复、氧疗和症状管理应纳入整体护理。
局限性
- 证据缺乏领域包括更广泛的IPF严重程度谱和合并症治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease (ILD) of unknown aetiology with a median survival of only 2-5 years. It is characterized by progressive dyspnoea and worsening lung function, ultimately resulting in death. Until recently, there were no effective therapies for IPF; however, with the publication of two landmark clinical trials in 2014, the anti-fibrotic therapies, nintedanib and pirfenidone, have gained widespread approval. This position paper aims to highlight the current evidence for the treatment of IPF, with particular application to the Australian and New Zealand population. We also consider areas in which evidence is currently lacking, especially with regard to the broader IPF severity spectrum and treatment of co-morbid conditions. The utility of non-pharmacological therapies including pulmonary rehabilitation, oxygen as well as symptom management thought to be important in the holistic care of IPF patients are also discussed.
引用
- Jo HE, Troy LK, Keir G, et al. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology. 2017. PMID: 28845557. doi:10.1111/resp.13146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。